Lazard Asset Management’s Stemline Therapeutics, Inc. STML Stock Holding History

Lazard Asset Management’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,116	Closed	-$11K	–	1828
2019 Q4	$11K	Hold	1,116	–	–	﹤0.01%	1384
2019 Q3	$11K	Buy	+1,116	New	+$14.6K	﹤0.01%	1301
2018 Q2	–	Sell	-78,034	Closed	-$1.19M	–	1151
2018 Q1	$1.19M	Buy	+78,034	New	+$1.22M	﹤0.01%	692
2014 Q1	–	Sell	-32,350	Closed	-$634K	–	1079
2013 Q4	$634K	Buy	+32,350	New	+$863K	﹤0.01%	740

Other funds holding STML

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Lazard Asset Management's STML Position: Q1 2020 in Review

Lazard Asset Management sold out of Stemline Therapeutics, Inc. (STML) in Q1 2020, closing a stake of 1,116 shares — an estimated $11K sold.

Lazard Asset Management first reported a position in STML in Q4 2013 and held it in 4 quarters. The position peaked at $1.19M in Q1 2018. 94 funds tracked by Wall St. Rank hold STML as of Q1 2020.

Lazard Asset Management reported no remaining Stemline Therapeutics, Inc. position as of Q1 2020 after selling out during the quarter.
Lazard Asset Management sold 1,116 Stemline Therapeutics, Inc. shares in Q1 2020, an estimated $11K.
Lazard Asset Management first reported a position in Stemline Therapeutics, Inc. in Q4 2013 and held it in 4 quarters.
Lazard Asset Management's Stemline Therapeutics, Inc. position peaked at $1.19M in Q1 2018.
94 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q1 2020.

Based on Lazard Asset Management's 13F filing for Q1 2020, filed 14 May 2020.